Drug Profile
BI 14332
Alternative Names: BI-14332-CL; BI14332Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Antihyperglycaemics; Piperidines; Pyridines; Xanthines
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 07 Aug 2014 Discontinued - Phase-I for Type-2 diabetes mellitus in Germany (PO)
- 30 Nov 2006 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02212938)
- 30 Nov 2006 Boehringer Ingelheim initiates enrolment in a phase I trial for Type-2 diabetes mellitus in Germany (NCT02212925)